Futura Medical is at an exciting juncture, with pivotal Eroxon® data due by mid-2016 and EU filings of TPR100 & TIB200 targeted for the end of the year. Regulatory approval of the change in manufacturing process for CSD500 (enabling a longer shelf life) is also expected this year. We have adopted a more conservative stance on the CSD500 rollout through partners, incl. first significant revenue in 2017e (from 2016).
